Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A group of markers and applications and kits for predicting cytokines and thrombosis storm of 2019 coronavirus disease

A technology of cytokines and group cells, which is applied in the field of biomedicine, can solve problems such as unclear research conclusions, and achieve the effects of broad application prospects, rapid detection, and low cost

Active Publication Date: 2022-05-20
BEIJING IMMUPEUTICS MEDICINE TECH LTD
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are few reports on the predictive markers of "thrombotic storm", and the research conclusions are not yet clear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A group of markers and applications and kits for predicting cytokines and thrombosis storm of 2019 coronavirus disease
  • A group of markers and applications and kits for predicting cytokines and thrombosis storm of 2019 coronavirus disease
  • A group of markers and applications and kits for predicting cytokines and thrombosis storm of 2019 coronavirus disease

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0033] In the present invention, the preparation method of the kit preferably includes the following steps:

[0034] (1) Will be coated with VEGF-D, TNF-α, SCF, LIF, IL-2, IL-4, IL-6, IL-8, IL-10, IL-15, IL-17A, IL- 18. One or more capture antibodies of IL-1β and IFN-γ are coupled to the encoded microspheres to obtain a protein coated with VEGF-D, TNF-α, SCF, LIF, IL-2, IL-4 , IL-6, IL-8, IL-10, IL-15, IL-17A, IL-18, IL-1β and IFN-γ one or two or more encoding microspheres of capture antibodies;

[0035] (2) In VEGF-D, TNF-α, SCF, LIF, IL-2, IL-4, IL-6, IL-8, IL-10, IL-15, IL-17A, IL-18, IL- One or more detection antibodies of 1β and IFN-γ are linked with biotin respectively to obtain biotin-labeled VEGF-D, TNF-α, SCF, LIF, IL-2, IL-4, IL- 6. Detection antibodies for one or more of IL-8, IL-10, IL-15, IL-17A, IL-18, IL-1β and IFN-γ;

[0036] There is no sequence relationship between the steps (1) and (2).

[0037] The present invention combines VEGF-D, TNF-α, SCF, LIF, IL-...

Embodiment 1

[0062] For VEGF-D, TNF-α, SCF, LIF, IL-2, IL-4, IL-6, IL-8, IL-10, IL-15, IL-17A, IL-18, IL-1β and Preparation of a liquid chip kit for IFN-γ biomarker detection.

[0063] 1. Kit Composition

[0064] (1) 14-plex coated microspheres: containing VEGF-D, TNF-α, SCF, LIF, IL-2, IL-4, IL-6, IL-8, IL-10, IL- 15. Microspheres encoding IL-17A, IL-18, IL-1β and IFN-γ capture antibodies;

[0065] (2) 14-plex biotin-labeled detection antibodies: VEGF-D, TNF-α, SCF, LIF, IL-2, IL-4, IL-6, IL-8, IL-10, IL-15, IL-17A, IL-18, IL-1β and IFN-γ detection antibodies;

[0066] (3) streptavidin phycoerythrin.

[0067] Among them, capture antibodies VEGF-D, TNF-α, SCF, LIF, IL-2, IL-4, IL-6, IL-8, IL-10, IL-15, IL-17A, IL-18, IL- The clone numbers of 1β and IFN-γ are 106, 28401, 5E9, 1F10, SP176, 8D4-8, 3G9, 6E7-C11-C9, JES3-9D7, 3D4, 4H1524.1, EPR19954-188, 3E1 and XMG1, respectively. 2; The clone numbers of VEGF-D, TNF-α, SCF, IL-4, IL-6, IL-8, IL-17A, IL-18, IL-1β and IFN-γ detection antib...

Embodiment 2

[0089] VEGF-D, TNF-α, SCF, LIF, IL-2, IL-4, IL-6, IL-8, IL-10, IL-15, IL-17A, IL-18, IL-1β and IFN- Application of gamma liquid chip kit in predicting COVID-19 cytokine release syndrome and thrombotic storm.

[0090] 1. Purpose of the experiment

[0091] Demonstrated VEGF-D, TNF-α, SCF, LIF, IL-2, IL-4, IL-6, IL-8, IL-10, IL-15, IL-17A, IL-18, IL-1β and IFN Baseline concentrations of -γ on admission were high in COVID-19 patients with cytokine release syndrome and thrombotic storm.

[0092] 2. Subjects

[0093] 1) On the premise of informed consent and meeting the inclusion conditions, select the enrolled cases and record personal basic information. The cohort of COVID-19 patients came from 24 COVID patients in Beijing Ditan Hospital Affiliated to Capital Medical University, including 14 critically ill patients and 10 critically ill patients. .

[0094] 2) Plasma was drawn from the patients before treatment when they were admitted to the hospital, and the samples were sto...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a group of markers for predicting cytokine release syndrome and thrombosis of 2019 coronavirus disease and its application, kit and preparation method of the kit, belonging to the technical field of biomedicine. The markers of the present invention are VEGF-D, TNF-α, SCF, LIF, IL-2, IL-4, IL-6, IL-8, IL-10, IL-15, IL-17A, IL-17A, IL-8, respectively 18. IL-1β and IFN-γ. VEGF-D, TNF-α, SCF, LIF, IL-2, IL-4, IL-6, IL-8, IL-10, IL-15, IL-17A, IL-18, IL-18 provided by the present invention A group of ‑1β, IFN‑γ markers or the prepared kits can be used to predict the cytokine release syndrome and thrombosis storm of coronavirus disease 2019 (COVID‑19), which has the advantages of rapid detection, accuracy, and low cost. bright future.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to a group of markers for predicting the cytokine release syndrome and thrombosis storm of coronavirus disease 2019 (COVID-19) and its application, kit and preparation method of the kit. Background technique [0002] Data show that since the outbreak of coronavirus disease 2019 (COVID-19), about 15% of COVID-19 patients have developed severe disease, and 5% to 6% of patients have developed critical disease. The fatality rate of critically ill patients with COVID-19 is significantly higher than that of critically ill patients. "Cytokine release syndrome and thrombotic storm" have been reported to be associated with critical illness and lethality in patients with COVID-19. Therefore, there is an urgent need to develop markers that can effectively predict "cytokine release syndrome and thrombosis storm" early to distinguish severe patients from critically ill patients,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/74G01N33/68G01N33/569G01N33/543
CPCG01N33/74G01N33/6863G01N33/6869G01N33/6866G01N33/56983G01N33/54313
Inventor 沈宁陈莉陈衍辉王修芳宋瑾
Owner BEIJING IMMUPEUTICS MEDICINE TECH LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com